Cancer Institute Payline Crashes to 4th Percentile Under NIH Overhaul
March 29, 2026 · 2 min read
Claire Cummings
The National Cancer Institute has tightened its payline to the 4th percentile — down from the 9th percentile just months ago — making it one of the most competitive funding environments in the institute's history. The shift means that even grant proposals scoring in the top 5% of reviewed applications may not receive funding.
From 700 Grants to 400 in a Single Year
NCI awarded just 400 new grants in fiscal year 2025, roughly 300 fewer than the 700 it had anticipated. The culprit: NIH's forward funding mandate, which requires institutes to disburse multi-year grant awards as single lump sums rather than annual installments. The policy, which applied to roughly 40% of new NIH grants in FY 2025, consumed budget capacity that would have otherwise supported hundreds of additional awards.
The numbers are stark. At NCI, the odds of a scientist's proposal succeeding have plummeted from roughly one in 10 to one in 25. The institute's $7.35 billion FY 2026 appropriation — a $128 million increase over FY 2025 — offers modest relief, but forward funding obligations will continue consuming a disproportionate share of available dollars.
Congress has capped FY 2026 forward funding at FY 2025 levels, providing a partial brake on the policy's acceleration. But the structural math remains punishing. NIH estimates approximately 970 fewer new grants across all institutes in FY 2026, with that proportion rising to 100% forward-funded by fiscal year 2027.
What Cancer Researchers Should Do Now
Brandon Schuff, a University of Providence chemist, told Chemical & Engineering News that securing federal funding has become a "pipe dream" under current conditions. Jeremy M. Berg, a veteran NIH watcher, notes that valuable research will be denied funding purely because of tighter competition, not lack of merit.
For cancer researchers navigating this landscape, diversification is no longer optional. Researchers should explore NCI's continued support for high-priority areas and consider collaborative, multi-institutional proposals that align with the institute's strategic plan. Foundation funding, international collaborations, and industry partnerships all deserve fresh attention. Tools like grantedai.com can help identify alternative federal, foundation, and international sources that match your research profile.
With the 4th-percentile reality setting in, the margin for strategic error is razor-thin. For deeper analysis of NIH funding strategies and alternative cancer research opportunities, visit the Granted blog.